Patents by Inventor Olivier Morales

Olivier Morales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyropheophorbide conjugate and use thereof in the treatment of cancer and as a fluorescent marker
    Patent number: 11975072
    Abstract: The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: May 7, 2024
    Inventors: Henri Azais, Pierre Collinet, Nadira Delhem-Fellahi, Olivier Morales, Serge Mordon, Céline Frochot, Régis Vanderesse, Aurélie Stallivieri
  • PYROPHEOPHORBIDE CONJUGATE AND USE THEREOF IN THE TREATMENT OF CANCER AND AS A FLUORESCENT MARKER
    Publication number: 20220378914
    Abstract: The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.
    Type: Application
    Filed: July 20, 2018
    Publication date: December 1, 2022
    Inventors: Henri AZAIS, Pierre COLLINET, Nadira DELHEM-FELLAHI, Olivier MORALES, Serge MORDON, Céline FROCHOT, Régis VANDERESSE, Aurélie STALLIVIERI
  • Antibody which is Directed Against Galectin-9 and is an Inhibitor of the Suppressor Activity of Regulatory T Lymphocytes
    Publication number: 20210107984
    Abstract: The disclosure relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 15, 2021
    Applicants: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, Universite Paris Saclay
    Inventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
  • Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes
    Patent number: 10899838
    Abstract: The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: January 26, 2021
    Assignees: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, Universite Paris-Saclay
    Inventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
  • ANTIBODY WHICH IS DIRECTED AGAINST GALECTIN-9 AND IS AN INHIBITOR OF THE SUPPRESSOR ACTIVITY OF REGULATORY T LYMPHOCYTES
    Publication number: 20170283499
    Abstract: The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
    Type: Application
    Filed: June 5, 2015
    Publication date: October 5, 2017
    Inventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
  • T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof
    Publication number: 20090130134
    Abstract: The invention relates to immunogenic peptides from EBV type I and II latency antigens, comprising at least one T CD4+ epitope which can be recognized by the majority of individuals in the Caucasian population. The invention also relates to the diagnostic and therapeutic applications of same.
    Type: Application
    Filed: February 2, 2006
    Publication date: May 21, 2009
    Inventors: Veronique Pancre, Claude Auriault, Stephane Depil, Bernard Maillere, Olivier Morales, Gaetan Munier